Cargando…

The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer

Detalles Bibliográficos
Autor principal:	Hofman, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154477/ https://www.ncbi.nlm.nih.gov/pubmed/32309300 http://dx.doi.org/10.21037/atm.2020.01.91

Ejemplares similares

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study
por: Xiao, Zhiwei, et al.
Publicado: (2022)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer
por: Lim, Jeong Uk, et al.
Publicado: (2021)

Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
por: Bianco, Andrea, et al.
Publicado: (2019)

Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis
por: Chun, Sang Hoon, et al.
Publicado: (2011)

Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer
por: Furqan, Muhammad, et al.
Publicado: (2022)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer
por: Lu, Shun, et al.
Publicado: (2022)

Adjuvant chemotherapy for locally advanced non-small cell lung cancer: still state of the art or an outdated therapy?
por: Schlachtenberger, Georg, et al.
Publicado: (2023)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy
por: Lee, Hee Yeon, et al.
Publicado: (2019)

Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report
por: Yang, Jie, et al.
Publicado: (2021)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR)
por: Udagawa, Hibiki, et al.
Publicado: (2021)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
por: Matsubara, Taichi, et al.
Publicado: (2021)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study
por: Joshi, Amit, et al.
Publicado: (2018)

Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis
por: Xiao, Huai-Qing, et al.
Publicado: (2016)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
por: Zhang, Longfeng, et al.
Publicado: (2020)

Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma
por: Zhu, Fubin, et al.
Publicado: (2023)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

NANOG as an adverse predictive marker in advanced non–small cell lung cancer treated with platinum-based chemotherapy
por: Chang, Boksoon, et al.
Publicado: (2017)

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Polymorphisms in the Gene Encoding Caspase 8 May Predict the Response to First-Line Platinum-Based Chemotherapy in Locally Advanced or Advanced Non-Small-Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2021)

Biomarkers predictive value in early stage non-small cell lung cancer
por: Malapelle, Umberto, et al.
Publicado: (2020)

Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
por: Nguyen, Khanh Toan, et al.
Publicado: (2023)

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
por: Rittberg, Rebekah, et al.
Publicado: (2022)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study
por: Wang, Wenzhong, et al.
Publicado: (2022)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

Effect of Cinobufacini plus platinum-based chemotherapy regimen on the immune function of patients with non-small-cell lung cancer: A meta-analysis
por: Zhao, Yisheng, et al.
Publicado: (2023)

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
por: Qiu, Bin, et al.
Publicado: (2021)

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
por: Wang, Chengdi, et al.
Publicado: (2019)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u8gg09vbngktljh84mcpttnjpt